Comments on: Alder Sets Stage for Showdown With Roche, With “Fast Follower” Antibody Drug Strategy http://www.xconomy.com/seattle/2008/09/18/alder-sets-stage-for-showdown-with-roche-with-fast-follower-antibody-drug-strategy/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 03:54:18 +0000 hourly 1 http://wordpress.org/?v=3.0.4 By: Actemra Rival IL-6 Inhibitor Shown Effective in Trial | RA Education | Rheumatoid Arthritis Warrior http://www.xconomy.com/seattle/2008/09/18/alder-sets-stage-for-showdown-with-roche-with-fast-follower-antibody-drug-strategy/comment-page-1/#comment-133022 Actemra Rival IL-6 Inhibitor Shown Effective in Trial | RA Education | Rheumatoid Arthritis Warrior Tue, 18 May 2010 13:36:43 +0000 http://www.xconomy.com/?p=4926#comment-133022 [...] the phase 2 trial began, Timmerman interviewed Randy Schatzman, CEO of Alder Biopharmaceuticals. “Alder has engineered the drug, called ALD518, to block the [...] [...] the phase 2 trial began, Timmerman interviewed Randy Schatzman, CEO of Alder Biopharmaceuticals. “Alder has engineered the drug, called ALD518, to block the [...]

]]>